Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2026 12:29 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025

Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to...
February 27, 2026 09:00 ET | Source: Global Alzheimer’s Platform Foundation®

Exceptional Clinical Trial Volunteers Presented National Citizen Scientist Awards for Research Efforts

WASHINGTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen...
February 25, 2026 10:30 ET | Source: MedSpa Pro

MedSpa Pro Announces Strategic Educational Partnership with A4M, Returns to Las Vegas for 2026

Boca Raton, Florida, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MedSpa Pro, a leader in medical aesthetic education and training, has announced a new educational partnership with A4M, marking a significant...
February 24, 2026 16:09 ET | Source: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of...
February 24, 2026 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia

MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in...
February 24, 2026 03:00 ET | Source: Amber Therapeutics

Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US

Oxford, UK – 24 February 2026 – Amber Therapeutics today announced a series of updates to its business highlighting the significant progress it has made since closing its $100 million (£80 million)...
February 23, 2026 10:31 ET | Source: Research and Markets

Continuing Medical Education (CME) Market Trends and Business Outlook 2026-2032 Featuring Yale, Harvard, Cleveland Clinic, Cambridge, Oxford and More

Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Continuing Medical Education Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The continuing...
February 20, 2026 17:11 ET | Source: Robbins LLP

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.

Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111
February 19, 2026 08:30 ET | Source: BioMedWire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution....
February 19, 2026 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Participate in Upcoming Events in February and March

MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics,...